Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | XDH | P47989 | 5/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16571180 | 0.88 | SLC22A12 (0.42) | PARP1XDHSLC22A12 | |
| SCHEMBL16571739 | 0.87 | XDH (0.40) | PARP1KDM1AXDHSLC22A12 | |
| SCHEMBL16571094 | 0.86 | PTGDR2 (0.41) | PTGDR2KIF11RXRARXRGXDH | |
| SCHEMBL19478363 | 0.85 | SCN9A (0.41) | PARP1XDHSLC22A12 | |
| SCHEMBL16571054 | 0.85 | NTRK1 (0.40) | KDM1AXDHSLC22A12 | |
| SCHEMBL16571716 | 0.84 | MAP2 (0.43) | PARP1KDM1AXDHSLC22A12ALDH1A1 | |
| SCHEMBL19478158 | 0.84 | GRM2 (0.45) | KDM1AXDHSLC22A12 | |
| SCHEMBL16571181 | 0.84 | CCNC (0.51) | XDHSLC22A12 | |
| SCHEMBL16571408 | 0.83 | IKBKB (0.40) | PTGDR2RXRARXRGPARP1KDM1A | |
| SCHEMBL16571095 | 0.83 | PSEN1 (0.42) | PTGDR2RXRARXRGPARP1XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3044207-B1 | INDOL-CARBOXAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-10-18 | — | — | EP | claimed |
| US-9464049-B2 | Indole-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2016-10-11 | — | — | US | claimed |
| US-20160185721-A1 | INDOLE-CARBOXAMIDES | HOFFMANN-LA ROCHE INC. (US) | 2016-06-30 | — | — | US | claimed |
| EP-3044207-B1 | INDOL-CARBOXAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-10-18 | — | — | EP | disclosed |
| EP-3044207-B1 | INDOL-CARBOXAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-10-18 | — | — | EP | disclosed |
| US-9464049-B2 | Indole-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-9464049-B2 | Indole-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-9464049-B2 | Indole-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2016-10-11 | — | — | US | disclosed |
| EP-3044207-A1 | INDOL-CARBOXAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2016-07-20 | — | — | EP | disclosed |
| US-20160185721-A1 | INDOLE-CARBOXAMIDES | HOFFMANN-LA ROCHE INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160185721-A1 | INDOLE-CARBOXAMIDES | HOFFMANN-LA ROCHE INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160185721-A1 | INDOLE-CARBOXAMIDES | HOFFMANN-LA ROCHE INC. (US) | 2016-06-30 | — | — | US | disclosed |
| WO-2015036412-A1 | INDOL-CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-03-19 | — | — | WO | disclosed |
| WO-2015036412-A1 | INDOL-CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185721-A1 | INDOLE-CARBOXAMIDES | DRD2, HCRTR1, CDR2 | PTGDR2 1021/4885KIF11 2618/4885RXRA 1308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.